Boston Therapeutics, Inc. (OTCQB: BTHE) addresses unmet medical needs in diabetes and inflammatory diseases through the development, manufacturing and commercialization of novel compounds based on complex carbohydrate chemistry. The company’s initial product is comprised of: BTI320, a chewable drug candidate for prevention of diabetes and its complications; IPOXYN™, an anti-necrosis therapeutic agent targeting human and animal tissues and organ systems deprived of oxygen and in need of metabolic support; and  OXYFEX™, the only oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. For more information, visit the company’s website at www.bostonti.com